Tag: Fabry disease

First approved clinically in 1991 for Gaucher disease, enzyme replacement therapy (ERT) offers a lifeline for individuals with specific genetic disorders. But **how does enzyme replacement therapy work** to correct life-altering enzyme deficiencies and improve patient outcomes?

Approximately 1 in 40,000 to 60,000 males are affected by Fabry disease, for which Fabrazyme is a primary treatment. This authoritative guide explains exactly what is Fabrazyme used for, detailing its function and impact on patients with this rare genetic disorder.